<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107578">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01905163</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A01391-42</org_study_id>
    <nct_id>NCT01905163</nct_id>
  </id_info>
  <brief_title>Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients</brief_title>
  <acronym>CILOVE</acronym>
  <official_title>Prospective Study Assessing the Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinomatosis of Ovarian Origin, Tubal or Primary Peritoneal, in Chemosensitive Patients Treated by Neoadjuvant Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <authority>France: ANSM - Agence Nationale de Sécurité du Médicament</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective nonrandomized multicenter phase II study, will evaluate the possibility of
      performing a laparoscopic interval debulking  after a minimum of 3 cycles of chemotherapy in
      highly chemo-sensitive patients with advanced ovarian, tubal cancer or primary peritoneal.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>the rate of conversion to laparotomy</measure>
    <time_frame>surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Feasibility of the surgical laparoscopic management of interval debulking surgery will be assessed by the rate of conversion to laparotomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Port site metastases</measure>
    <time_frame>during 1 year post surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity: intraoperative and postoperative complications</measure>
    <time_frame>during surgery and 1 year post surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>during the hospital stay (an expected average of 5 days), at 1 week, 1 month, 3 and 6 months post surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using EORTC QLQ-C30</measure>
    <time_frame>before surgery (an expected average of 7 days before surgery), 1 week , 1 month, 3 and 6 months post-surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic evaluation</measure>
    <time_frame>1 year post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>economic evaluation will be assess by a quantification of the additional costs of surgery, duration and cost of hospitalization, number of possible re-interventions or hospitalizations.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Peritoneal Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>laparoscopic management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tumor Debulking Surgery by laparoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor Debulking Surgery by laparoscopy</intervention_name>
    <arm_group_label>laparoscopic management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; or = 18 years

          -  performance status WHO &lt; 2

          -  Epithelial ovarian, fallopian tubes or primary peritoneal carcinoma (histologically
             confirmed)

          -  Unresectable disease because of FIGO stage IV disease proven by imaging (CT Scan or
             PET CT) and/or diffuse extensive carcinosis considered unresectable for advanced FIGO
             stage IIIc; or patients unable to support a radical primary surgery because of age,
             comorbidities or altered general condition.

          -  No previous debulking surgery before neoadjuvant chemotherapy.

          -  Patients treated with a minimum of 3 cycles of platinum-based neoadjuvant
             chemotherapy.

          -  Response to chemotherapy was radiologically confirmed (Scan-TAP) prior to interval
             surgery:

        No evidence of peritoneal supra-mesocolic carcinomatosis ; Residual pelvic masses smaller
        than 10 cm ; Absence of suspect supra-centimeter retroperitoneal lymphadenopathy

          -  able to read, write and understand French.

          -  Member of a Social Security scheme.

          -  written informed consent.

        Exclusion Criteria:

          -  Patient unable to support laparoscopy

          -  psychiatric condition or social or geographic situation that would impede appropriate
             study participation

          -  Concomitant participation in another clinical trial evaluating surgical treatment
             (interfering with the evaluation of the main endpoint)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe POMEL, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie THIVAT, PhD</last_name>
    <phone>33473278089</phone>
    <email>emilie.thivat@cjp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Pomel, Pr</last_name>
      <phone>33473278121</phone>
    </contact>
    <investigator>
      <last_name>Christophe Pomel, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel Canis, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Michel Canis, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeth CHEREAU EWALD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elisabeth CHEREAU EWALD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie FOURCHOTTE, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Virginie Fourchotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Lecuru, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Fabrice Lecuru, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hôpital René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roman ROUZIER, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Roman ROUZIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud WATTIEZ, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Arnaud Wattiez, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gwénaël FERRON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gwénaël FERRON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>July 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Laparoscopy, interval debulking surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
